Attenuated XPC Expression Is Not Associated with Impaired DNA Repair in Bladder Cancer

Kishan Naipal, Anja Raams, Serena Bruens, Inger Brandsma, Nicole Verkaik, Koos Jaspers, Jan Hoeijmakers, Arno van Leenders, Joris Pothof, Roland Kanaar, Joost Boormans, Dik van Gent

Research output: Contribution to journalArticleAcademicpeer-review

9 Citations (Scopus)
5 Downloads (Pure)

Abstract

Bladder cancer has a high incidence with significant morbidity and mortality. Attenuated expression of the DNA damage response protein Xeroderma Pigmentosum complementation group C (XPC) has been described in bladder cancer. XPC plays an essential role as the main initiator and damage-detector in global genome nucleotide excision repair (NER) of UV-induced lesions, bulky DNA adducts and intrastrand crosslinks, such as those made by the chemotherapeutic agent Cisplatin. Hence, XPC protein might be an informative biomarker to guide personalized therapy strategies in a subset of bladder cancer cases. Therefore, we measured the XPC protein expression level and functional NER activity of 36 bladder tumors in a standardized manner. We optimized conditions for dissociation and in vitro culture of primary bladder cancer cells and confirmed attenuated XPC expression in approximately 40% of the tumors. However, NER activity was similar to co-cultured wild type cells in all but one of 36 bladder tumors. We conclude, that (i) functional NER deficiency is a relatively rare phenomenon in bladder cancer and (ii) XPC protein levels are not useful as biomarker for NER activity in these tumors.
Original languageUndefined/Unknown
JournalPLoS One (print)
Volume10
Issue number4
DOIs
Publication statusPublished - 2015

Cite this